Relay Therapeutics, Inc.RLAY

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$17.73
Market cap
$3.9B
P/E
—
Revenue (TTM)
$10.3M
Net income
-$286.0M
Dividend yield
—
1-year total return
304.8%
Net margin
-2763.6%
Revenue growth
23.9%
Debt / equity
—

What Relay Therapeutics, Inc. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$82.7M$3.0M$1.4M$25.5M$10.0M$15.4M
Net income-$52.4M-$363.9M-$290.5M-$342.0M-$337.7M-$276.5M
Free cash flow-$104.4M-$77.9M-$238.6M-$304.4M-$251.1M-$235.9M

More on RLAY.

Figures from Relay Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.